Lyell Immunopharma (NASDAQ:LYEL) Announces Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) issued its earnings results on Thursday. The company reported ($7.68) EPS for the quarter, missing the consensus estimate of ($2.15) by ($5.53), FiscalAI reports. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Lyell Immunopharma had a negative return on equity of 85.36% and a negative net margin of 762,355.56%.

Lyell Immunopharma Stock Down 14.2%

Shares of LYEL opened at $21.25 on Friday. The stock has a market cap of $451.35 million, a PE ratio of -1.30 and a beta of -0.14. Lyell Immunopharma has a 12-month low of $7.65 and a 12-month high of $45.00. The business has a 50-day simple moving average of $24.13 and a two-hundred day simple moving average of $21.47.

Insider Activity

In other news, CEO Lynn Seely sold 7,455 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $174,372.45. Following the sale, the chief executive officer directly owned 74,266 shares in the company, valued at approximately $1,737,081.74. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gary K. Lee sold 1,671 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $39,084.69. Following the completion of the transaction, the insider directly owned 16,938 shares of the company’s stock, valued at $396,179.82. This represents a 8.98% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 11,310 shares of company stock valued at $264,285. 22.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its holdings in Lyell Immunopharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock valued at $2,629,000 after purchasing an additional 5,913 shares during the period. ExodusPoint Capital Management LP bought a new position in Lyell Immunopharma during the 4th quarter worth $262,000. Marshall Wace LLP acquired a new position in Lyell Immunopharma during the 2nd quarter worth about $94,000. Two Sigma Investments LP grew its position in shares of Lyell Immunopharma by 107.0% in the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after buying an additional 10,768 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $382,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LYEL shares. Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They issued a “market outperform” rating and a $34.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. Finally, HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their price objective for the company from $20.00 to $45.00 in a research note on Tuesday, December 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $39.50.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.